US EditionNew Large-Scale Study Maps Early Triggers of Alzheimer’s Protein Aggregation
- On June 12, 2025, a collaborative team from the Wellcome Sanger Institute, CRG, and IBEC released a comprehensive study detailing the initial molecular processes involved in amyloid beta aggregation associated with Alzheimer's disease.
- The study arose from the urgent need for more effective treatments since current therapies mainly manage symptoms without slowing Alzheimer's progression.
- Using machine learning and genetically engineered yeast cells, the team analyzed over 140,000 Aβ42 peptide variants to create the first detailed map of how mutations alter aggregation energy landscapes.
- Dr. Anna Arutyunyan explained that by analyzing how more than 140,000 protein variants impact the process of amyloid beta aggregation—key to Alzheimer's disease—they have developed an unprecedented detailed model showing the influence of specific mutations on the energy dynamics of this aggregation.
- This method reveals that aggregation starts at the peptide's C-terminal region and offers a new path to targeted therapies, potentially advancing treatments for Alzheimer's and similar diseases.
15 Articles
15 Articles
Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer's Disease
TAINAN, June 13, 2025 /PRNewswire/ -- Merry Life Biomedical Company announces the launch of its global Phase II clinical trial for TML-6, a novel oral small molecule drug targeting early-stage Alzheimer's disease (AD). TML-6 combines multiple mechanisms, including anti-oxidative effects…
Scientists Have Developed a Synthetic “Mini Prion” That Mimics Alzheimer’s
The model enables the study of the fundamental interactions that underlie neurodegenerative disease. Researchers from Northwestern University and the University of California, Santa Barbara have engineered the first synthetic fragment of the tau protein that behaves like a prion, a type of misfolded protein known for its ability to propagate its abnormal shape to normal [...]
3D mapping reveals network-specific amyloid progression and subcortical susceptibility in mice
Alzheimer’s disease (AD) is a progressive, neurodegenerative dementia with no cure. Prominent hypotheses suggest accumulation of beta-amyloid (Aβ) contributes to neurodegeneration and memory loss, however identifying brain regions with early susceptibility to Aβ remains elusive. Using SWITCH to immunolabel intact brain, we created a spatiotemporal map of Aβ deposition in the 5XFAD mouse. We report that subcortical memory structures show primary …
UNC researchers to study Alzheimer's
Researchers at the University of North Carolina at Chapel Hill announced a $5 million federal grant to support groundbreaking research on potential treatments for Alzheimer's disease. The multi-year project aims to develop innovative therapies targeting early-stage cognitive decline and to…
New large-scale study maps early triggers of Alzheimer’s protein aggregation
A new large-scale study has mapped the first molecular events that drive the formation of harmful amyloid protein aggregates found in Alzheimer's disease, pointing towards a new potential therapeutic target.
Coverage Details
Bias Distribution
- 75% of the sources are Center
To view factuality data please Upgrade to Premium
